Table 3.
Primary and secondary outcomes among patients who adhered to the treatment regimen.
| Outcome measures | Atorvastatin | Rosuvastatin |
|---|---|---|
| Primary outcomes | ||
| mRS score of 0 at 3 months | ||
| No of total patients | 1890 | 458 |
| No of events | 789 | 205 |
| Event rate (%) | 41.75% | 44.76% |
| Absolute rate difference | Reference | 3.01 |
| Relative rate (95% CI) | Reference | 1.12 (1.01, 1.24) |
| P value | Reference | 0.028 |
| E value (95% LCI) | Reference | 1.49 (1.11) |
| Secondary outcomes | ||
| mRS score of 0 at discharge | ||
| No of total patients | 2581 | 713 |
| No of events | 848 | 276 |
| Event rate (%) | 32.86% | 38.71% |
| Absolute rate difference | Reference | 5.85 |
| Relative rate (95% CI) | Reference | 1.20 (1.09, 1.23) |
| P value | Reference | 0.0002 |
| E value (95% LCI) | Reference | 1.69 (1.40) |
| mRS score of 0 at 6 months | ||
| No of total patients | 1657 | 379 |
| No of events | 756 | 201 |
| Event rate (%) | 45.62% | 53.03% |
| Absolute rate difference | Reference | 7.41 |
| Relative rate (95% CI) | Reference | 1.18 (1.06, 1.29) |
| P value | Reference | 0.0010 |
| E value (95% LCI) | Reference | 1.64 (1.31) |
| mRS score of 0 at 12 months | ||
| No of total patients | 1401 | 289 |
| No of events | 692 | 161 |
| Event rate (%) | 49.39% | 55.71% |
| Absolute rate difference | Reference | 6.32 |
| Relative rate (95% CI) | Reference | 1.16 (1.03, 1.28) |
| P value | Reference | 0.0072 |
| E value (95% LCI) | Reference | 1.59 (1.21) |
| Stroke recurrence in 12 months | ||
| No of total patients | 1401 | 289 |
| No of events | 62 | 13 |
| Event rate (%) | 4.43% | 4.50% |
| Median (P25, P75) follow-up days | 367 (364, 376) | 369 (365, 380) |
| Absolute rate difference | Reference | 0.57 |
| Hazard ratio (95% CI) | Reference | 0.98 (0.54, 1.78) |
| P value | Reference | 0.95 |
| E value (95% UCI) | Reference | 1.16 (1.00) |
| All-cause mortality in 12 months | ||
| No of total patients | 1401 | 289 |
| No of events | 6 | 1 |
| Event rate (%) | 0.43% | 0.35% |
| Median (P25, P75) follow-up days | 368 (365, 377) | 370 (365, 382) |
| Absolute rate difference | Reference | 0.08 |
| Hazard ratio (95% CI) | Reference | 0.98 (0.12, 8.28) |
| P value | Reference | 0.98 |
| E value (95% UCI) | Reference | 1.16 (1.00) |
| Cardiovascular mortality in 12 months | ||
| No of total patients | 1401 | 289 |
| No of events | 3 | 0 |
| Event rate (%) | 0.21% | 0.00% |
| Median (P25, P75) follow-up days | 368 (365, 377) | 370 (365, 382) |
| Absolute rate difference | Reference | 0.21 |
| Hazard ratio (95% CI) | Reference | NA |
| P value | Reference | NA |
| E value (95% CI) | Reference | NA |
| MACE in 12 months | ||
| No of total patients | 1401 | 289 |
| No of events | 68 | 13 |
| Event rate (%) | 4.85% | 4.50% |
| Median (P25, P75) follow-up days | 367 (364, 376) | 369 (365, 380) |
| Absolute rate difference | Reference | 0.35 |
| Hazard ratio (95% CI) | Reference | 0.90 (0.50, 1.62) |
| P value | Reference | 0.71 |
| E value (95% UCI) | Reference | 1.46 (1.00) |
CI, confidence interval; LCI lower confidence interval; MACE, major adverse cardiovascular events; mRS, modified Rankin Scale; NA, not applicable; NNT, number needed to treat; P25, 25th percentile; P75, 75th percentile; UCI, upper confidence interval.